Vaccine breakthrough infection leads to distinct profiles of neutralizing antibody responses by SARS-CoV-2 variant.

Autor: Seaman MS; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.; Harvard Medical School, Boston, Massachusetts, USA., Siedner MJ; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA., Boucau J; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA., Lavine CL; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Ghantous F; Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA., Liew MY; Massachusetts General Hospital, Boston, Massachusetts, USA., Mathews JI; Massachusetts General Hospital, Boston, Massachusetts, USA., Singh A; Massachusetts General Hospital, Boston, Massachusetts, USA., Marino C; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA., Regan J; Brigham and Women's Hospital Boston, Massachusetts, USA., Uddin R; Massachusetts General Hospital, Boston, Massachusetts, USA., Choudhary MC; Brigham and Women's Hospital Boston, Massachusetts, USA., Flynn JP; Brigham and Women's Hospital Boston, Massachusetts, USA., Chen G; Massachusetts General Hospital, Boston, Massachusetts, USA., Stuckwisch AM; Massachusetts General Hospital, Boston, Massachusetts, USA., Lipiner T; Massachusetts General Hospital, Boston, Massachusetts, USA., Kittilson A; Brigham and Women's Hospital Boston, Massachusetts, USA., Melberg M; Brigham and Women's Hospital Boston, Massachusetts, USA., Gilbert RF; Massachusetts General Hospital, Boston, Massachusetts, USA., Reynolds Z; Massachusetts General Hospital, Boston, Massachusetts, USA., Iyer SL; Massachusetts General Hospital, Boston, Massachusetts, USA., Chamberlin GC; Massachusetts General Hospital, Boston, Massachusetts, USA., Vyas TD; Massachusetts General Hospital, Boston, Massachusetts, USA., Vyas JM; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA., Goldberg MB; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA., Luban J; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA.; UMass Med School, Worcester, Massachusetts, USA., Li JZ; Harvard Medical School, Boston, Massachusetts, USA.; Brigham and Women's Hospital Boston, Massachusetts, USA., Barczak AK; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, Massachusetts, USA., Lemieux JE; Harvard Medical School, Boston, Massachusetts, USA.; Massachusetts General Hospital, Boston, Massachusetts, USA.; Broad Institute, Cambridge, Massachusetts, USA.
Jazyk: angličtina
Zdroj: JCI insight [JCI Insight] 2022 Oct 10; Vol. 7 (19). Date of Electronic Publication: 2022 Oct 10.
DOI: 10.1172/jci.insight.159944
Abstrakt: Protective immunity against SARS-CoV-2 infection after COVID-19 vaccination may differ by variant. We enrolled vaccinated (n = 39) and unvaccinated (n = 11) individuals with acute, symptomatic SARS-CoV-2 Delta or Omicron infection and performed SARS-CoV-2 viral load quantification, whole-genome sequencing, and variant-specific antibody characterization at the time of acute illness and convalescence. Viral load at the time of infection was inversely correlated with antibody binding and neutralizing antibody responses. Across all variants tested, convalescent neutralization titers in unvaccinated individuals were markedly lower than in vaccinated individuals. Increases in antibody titers and neutralizing activity occurred at convalescence in a variant-specific manner. For example, among individuals infected with the Delta variant, neutralizing antibody responses were weakest against BA.2, whereas infection with Omicron BA.1 variant generated a broader response against all tested variants, including BA.2.
Databáze: MEDLINE